Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma

The added value of capecitabine to adjuvant gemcitabine monotherapy (GEM) in pancreatic ductal adenocarcinoma (PDAC) was shown by the ESPAC‐4 trial. Real‐world data on the effectiveness of gemcitabine plus capecitabine (GEMCAP), in patients ineligible for mFOLFIRINOX, are lacking. Our study assessed...

Descripción completa

Detalles Bibliográficos
Autores principales: de Jong, Evelien J. M., Janssen, Quisette P., Simons, Tessa F. A., Besselink, Marc G., Bonsing, Bert A., Bouwense, Stefan A. W., Geurts, Sandra M. E., Homs, Marjolein Y. V., de Meijer, Vincent E., Tjan‐Heijnen, Vivianne C. G., van Laarhoven, Hanneke W. M., Valkenburg‐van Iersel, Liselot B. J., Wilmink, Johanna W., van der Geest, Lydia G., Koerkamp, Bas Groot, de Vos‐Geelen, Judith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303436/
https://www.ncbi.nlm.nih.gov/pubmed/34935139
http://dx.doi.org/10.1002/ijc.33916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303436/
https://www.ncbi.nlm.nih.gov/pubmed/34935139
http://dx.doi.org/10.1002/ijc.33916

Ejemplares similares